Schmid C, Richer M, Bilenge CM, Josenando T, Chappuis F, et al.
2005-06-01 • Journal of Infectious Diseases
2005-06-01 • Journal of Infectious Diseases
BACKGROUND: Treatment of late-stage human African trypanosomiasis (HAT) with melarsoprol can be improved by shortening the regimen. A previous trial demonstrated the safety and efficacy ...
Signorell A, Hetzel M, Tshefu AK, Omoluabi E, Awor P, et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
INTRODUCTION In sub-Saharan Africa, over 400,000 children die annually from malaria and other preventable illnesses. Little is known about where these children die, from which causes...
Burri C, Yeramian PD, Allen JL, Merolle A, Serge KK, et al.
2016-02-16 • PLOS Neglected Tropical Diseases
2016-02-16 • PLOS Neglected Tropical Diseases
BACKGROUND Sleeping sickness (human African trypanosomiasis [HAT]) is caused by protozoan parasites and characterized by a chronic progressive course, which may last up to several ye...
Legros D, Ollivier G, Gastellu-Etchegorry M, Paquet C, Burri C, et al.
2002-07-01 • Lancet Infectious Diseases
2002-07-01 • Lancet Infectious Diseases
Human African trypanosomiasis re-emerged in the 1980s. However, little progress has been made in the treatment of this disease over the past decades. The first-line treatment for second-...
Human African trypanosomiasis (sleeping sickness) occurs in sub-Saharan Africa. It is caused by the protozoan parasite Trypanosoma brucei, transmitted by tsetse flies. Almost all cases a...
